FGP
ANIP icon

Freestone Grove Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Freestone Grove Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.6M Buy
254,230
+113,121
+80% +$8.83M 0.14% 212
2025
Q4 		$11.1M Buy
141,109
+110,425
+360% +$9.56M 0.08% 279
2025
Q3 		$2.81M Sell
30,684
-164,530
-84% -$13.4M 0.02% 355
2025
Q2 		$12.7M Buy
195,214
+191,217
+4,784% +$12.4M 0.1% 254
2025
Q1 		$268K Sell
3,997
-682
-15% -$40.7K ﹤0.01% 494
2024
Q4 		$259K Buy
+4,679
New +$269K ﹤0.01% 492

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Freestone Grove Partners's ANIP Position: Q1 2026 in Review

Freestone Grove Partners increased its ANI Pharmaceuticals (ANIP) stake by 80% in Q1 2026, buying an estimated $8.83M and bringing the position to 254,230 shares worth $19.6M. The position accounts for 0.14% of the portfolio, ranked #212.

Freestone Grove Partners first reported a position in ANIP in Q4 2024 and has held it in 6 quarters since. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Freestone Grove Partners held 254,230 shares of ANI Pharmaceuticals worth $19.6M as of Q1 2026.
  • Freestone Grove Partners bought 113,121 ANI Pharmaceuticals shares in Q1 2026, an estimated $8.83M.
  • ANI Pharmaceuticals made up 0.14% of Freestone Grove Partners's portfolio in Q1 2026, its #212 holding.
  • Freestone Grove Partners first reported a position in ANI Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.